These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
524 related articles for article (PubMed ID: 38612640)
21. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Elsaid MI; Li N; Firkins SA; Rustgi VK; Paskett ED; Acharya C; Reddy KR; Chiang CW; Mumtaz K Aliment Pharmacol Ther; 2024 May; 59(9):1096-1110. PubMed ID: 38538967 [TBL] [Abstract][Full Text] [Related]
22. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743 [TBL] [Abstract][Full Text] [Related]
23. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Girard J Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624 [TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide. Nauck MA; Mirna AEA; Quast DR Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380 [TBL] [Abstract][Full Text] [Related]
25. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931 [TBL] [Abstract][Full Text] [Related]
26. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Liu QK Front Endocrinol (Lausanne); 2024; 15():1431292. PubMed ID: 39114288 [TBL] [Abstract][Full Text] [Related]
27. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Thondam SK; Cuthbertson DJ; Wilding JPH Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125 [TBL] [Abstract][Full Text] [Related]
28. [Gastrointestinal hormones: their increasing pharmacotherapeutic relevance in metabolic diseases]. Gallwitz B Inn Med (Heidelb); 2023 Feb; 64(2):205-210. PubMed ID: 36598526 [TBL] [Abstract][Full Text] [Related]
29. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Andreasen CR; Andersen A; Vilsbøll T Diabetologia; 2023 Oct; 66(10):1846-1858. PubMed ID: 37498367 [TBL] [Abstract][Full Text] [Related]
30. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Targher G; Mantovani A; Byrne CD Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):179-191. PubMed ID: 36620987 [TBL] [Abstract][Full Text] [Related]
31. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review. Mathiesen DS; Bagger JI; Bergmann NC; Lund A; Christensen MB; Vilsbøll T; Knop FK Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443356 [TBL] [Abstract][Full Text] [Related]
32. Incretins yesterday, pleiotropic gastrointestinal hormones today:glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Kiec-Klimczak ME; Pach DM; Pogwizd ME; Hubalewska-Dydejczyk AB Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):176-82. PubMed ID: 21913887 [TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves. Mayer F; Gunawan AL; Tso P; Aponte GW Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358 [TBL] [Abstract][Full Text] [Related]
34. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review. Mima A; Nomura A; Fujii T Biomed Pharmacother; 2023 Sep; 165():115032. PubMed ID: 37331253 [TBL] [Abstract][Full Text] [Related]
35. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121 [TBL] [Abstract][Full Text] [Related]